Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.50 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | F2R | P25116 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31354705 | 0.83 | GABRA1 (0.44) | GABRA1GABRB2CLCN2TSHRF2R | |
| SCHEMBL6546236 | 0.82 | GABRA1 (0.48) | GABRA1GABRB2CLCN2TSHRF2R | |
| SCHEMBL2935940 | 0.82 | GABRA1 (0.48) | GABRA1GABRB2CLCN2TSHRF2R | |
| SCHEMBL27367606 | 0.82 | GABRA1 (0.48) | GABRA1GABRB2CLCN2TSHRF2R | |
| SCHEMBL5934500 | 0.82 | GABRA1 (0.48) | GABRA1GABRB2CLCN2TSHRF2R | |
| SCHEMBL17331003 | 0.80 | GABRA1 (0.46) | GABRA1GABRB2CLCN2TSHRF2R | |
| SCHEMBL28115 | 0.80 | FOLH1 (0.61) | CLCN2TSHRALDH1A1TP53HTT | |
| SCHEMBL254888 | 0.80 | HSD17B1 (0.48) | GABRA1GABRB2CLCN2TSHRF2R | |
| SCHEMBL817149 | 0.80 | GABRA1 (0.46) | GABRA1GABRB2CLCN2TSHRF2R | |
| SCHEMBL4268183 | 0.80 | GABRA1 (0.46) | GABRA1GABRB2CLCN2TSHRF2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7232634-B2 | Charge generating layer and a charge transport layer with bulky organic groups to prevent recrystallization of the charge transport molecule and shield the nitrogen from molecular attack; oxidation reisitance, wear resistance | XEROX CORPORATION (US) | 2007-06-19 | — | — | US | claimed |
| EP-2380567-B1 | MELANIN PRODUCTION INHIBITOR | POLA CHEM IND INC (JP) | 2019-01-16 | — | — | EP | disclosed |
| EP-3009123-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2845587-A2 | Melanin production inhibitor | Pola Chemical Industries Inc. (JP) | 2015-03-11 | — | — | EP | disclosed |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8846012-B2 | Melanin production inhibitor | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-2380567-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
| US-7232634-B2 | Charge generating layer and a charge transport layer with bulky organic groups to prevent recrystallization of the charge transport molecule and shield the nitrogen from molecular attack; oxidation reisitance, wear resistance | XEROX CORPORATION (US) | 2007-06-19 | — | — | US | disclosed |
| US-20060068309-A1 | Imaging member | XEROX CORPORATION | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, TH | GABRA1 335/4885GABRB2 772/4885CLCN2 3402/4885 |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | TYR, MC1R, F12 | GABRA1 334/4885GABRB2 727/4885CLCN2 3303/4885 |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, MC1R | GABRA1 360/4885GABRB2 737/4885CLCN2 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.